52950 Federal Register / Vol. 75, No. 167 / Monday, August 30, 2010 / Notices 

20892. The meeting will be open to the 

public with attendance limited to space 

available. The meeting will also be Web 

cast. 

The main agenda item will be a 

review of the revised draft report on 

genetics education and training and 

discussion of the final draft 

recommendations. The meeting will 

also include sessions on genomic data 

sharing and the implications of 

affordable whole-genome sequencing, 

an update on the implementation of the 

Genetic Information Nondiscrimination 

Act, and a briefing from the Food and 

Drug Administration on activities 

related to genetic testing. 

As always, the Committee welcomes 

hearing from anyone wishing to provide 

public comment on any issue related to 

genetics, health and society. Please note 

that because SACGHS operates under 

the provisions of the Federal Advisory 

Committee Act, all public comments 

will be made available to the public. 

Individuals who would like to provide 

public comment should notify the 

SACGHS Executive Secretary, Ms. Sarah 

Carr, by telephone at 301–496–9838 or 

e-mail at carrs@od.nih.gov. The 

SACGHS office is located at 6705 

Rockledge Drive, Suite 750, Bethesda, 

MD 20892. Anyone planning to attend 

the meeting who needs special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, is also asked to 

contact the Executive Secretary. 

Under authority of 42 U.S.C. 217a, 

Section 222 of the Public Health Service 

Act, as amended, the Department of 

Health and Human Services established 

SACGHS to serve as a public forum for 

deliberations on the broad range of 

human health and societal issues raised 

by the development and use of genetic 

and genomic technologies and, as 

warranted, to provide advice on these 

issues. The draft meeting agenda and 

other information about SACGHS, 

including information about access to 

the Web cast, will be available at the 

following Web site: http:// 

oba.od.nih.gov/SACGHS/ 

sacghs_meetings.html. 

Dated: August 24, 2010. 

Jennifer Spaeth, 

Director, NIH Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–21532 Filed 8–27–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Committee on Vital and Health 

Statistics: Meeting 

Pursuant to the Federal Advisory 

Committee Act, the Department of 

Health and Human Services (HHS) 

announces the following advisory 

committee meeting. 

Name: National Committee on Vital and 

Health Statistics (NCVHS), Full Committee 

Meeting. 

Time and Date: September 15, 2010 9 a.m.– 

2 p.m.; September 16, 2010 8:30 a.m.– 

12:30 p.m. 

Place: Embassy Suites Crystal City Hotel, 

1300 Jefferson Davis Highway, Arlington, VA 

22202, (703) 979–9799. 

Status: Open. 

Purpose: At this meeting the Committee 

will hear presentations and hold discussions 

on several health data policy topics. On the 

morning of the first day the Committee will 

hear updates from the Department, the Center 

for Medicare and Medicaid Services, and the 

Office of the National Coordinator for Health 

Information Technology. Draft letters to the 

HHS Secretary regarding the HIPAA national 

health plan identifier and operating rules on 

eligibility and claim status will also be 

discussed. In the afternoon there will be a 

discussion about a letter to the HHS 

Secretary regarding sensitive information in 

medical records. 

On the morning of the second day there 

will be a review of the final letters regarding 

the national health plan identifier, operating 

rules on eligibility and claim status, and 

sensitive information in medical records. 

Subcommittees will also present their 

reports. The afternoon of the second day will 

conclude with a discussion of the 60th 

Anniversary Symposium that was held in 

June 2010. 

The times shown above are for the full 

Committee meeting. Subcommittee breakout 

sessions can be scheduled for late in the 

afternoon of the first day and second day and 

in the morning prior to the full Committee 

meeting on the second day. Agendas for these 

breakout sessions will be posted on the 

NCVHS Web site (URL below) when 

available. 

Contact Person for More Information: 

Substantive program information as well as 

summaries of meetings and a roster of 

committee members may be obtained from 

Marjorie S. Greenberg, Executive Secretary, 

NCVHS, National Center for Health Statistics, 

Centers for Disease Control and Prevention, 

3311 Toledo Road, Room 2402, Hyattsville, 

Maryland 20782, telephone (301) 458–4245. 

Information also is available on the NCVHS 

home page of the HHS Web site: http:// 

www.ncvhs.hhs.gov/, where further 

information including an agenda will be 

posted when available. 

Should you require reasonable 

accommodation, please contact the CDC 

Office of Equal Employment Opportunity on 

(301) 458–4EEO (4336) as soon as possible. 

Dated: August 24, 2010. 

James Scanlon, 

Deputy Assistant Secretary for Planning and 

Evaluation (Science and Data Policy), Office 

of the Assistant Secretary for Planning and 

Evaluation. 

[FR Doc. 2010–21516 Filed 8–27–10; 8:45 am] 

BILLING CODE 4151–05–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the National Biodefense 

Science Board 

AGENCY: Department of Health and 

Human Services, Office of the Secretary. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Services is hereby giving notice that the 

National Biodefense Science Board 

(NBSB) will be holding a public 

meeting. The meeting is open to the 

public. 

DATES: The NBSB will hold a public 

meeting on September 22, 2010 from 8 

a.m. to 5 p.m. ET. The agenda is subject 

to change as priorities dictate. 

ADDRESSES: Washington, DC Metro 

Area. The venue details will be posted 

on the NBSB webpage at http:// 

www.phe.gov/Preparedness/legal/ 

boards/nbsb/Pages/default.aspx as they 

become available. 

FOR FURTHER INFORMATION CONTACT: Email: NBSB@HHS.GOV. 

SUPPLEMENTARY INFORMATION: Pursuant 

to section 319M of the Public Health 

Service Act (42 U.S.C. 247d–7f) and 

section 222 of the Public Health Service 

Act (42 U.S.C. 217a), the Department of 

Health and Human Services established 

the National Biodefense Science Board. 

The Board shall provide expert advice 

and guidance to the Secretary on 

scientific, technical, and other matters 

of special interest to the Department of 

Health and Human Services regarding 

current and future chemical, biological, 

nuclear, and radiological agents, 

whether naturally occurring, accidental, 

or deliberate. The Board may also 

provide advice and guidance to the 

Secretary on other matters related to 

public health emergency preparedness 

and response. 

Background: A portion of this public 

meeting will be dedicated to a report 

and presentation by the Disaster Mental 

Health Subcommittee to the NBSB on 

their assessment of the Department of 

Health and Human Services’ progress to 

better integrate behavioral health into 

emergency preparedness and response 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 167 / Monday, August 30, 2010 / Notices 52951 

activities. Subsequent agenda topics 

will be added as priorities dictate. 

Availability of Materials: The meeting 

agenda and materials will be posted on 

the NBSB Web site at http:// 

www.phe.gov/Preparedness/legal/ 

boards/nbsb/Pages/default.aspx prior to 

the meeting. 

Procedures for Providing Public Input: 

Any member of the public providing 

oral comments at the meeting must sign 

in at the registration desk and provide 

his/her name, address, and affiliation. 

All written comments must be received 

prior to September 21, and should be 

sent by e-mail to NBSB@HHS.GOV with 

‘‘NBSB Public Comment’’ as the subject 

line. Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

e-mail NBSB@HHS.GOV. 

Dated: August 10, 2010. 

Nicole Lurie, 

Assistant Secretary for Preparedness and 

Response. 

[FR Doc. 2010–21504 Filed 8–27–10; 8:45 am] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Agency for Healthcare Research 

and Quality, HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

intention of the Agency for Healthcare 

Research and Quality (AHRQ) to request 

that the Office of Management and 

Budget (OMB) approve the proposed 

information collection project: 

‘‘Understanding Patients’ Knowledge 

and Use of Acetaminophen—Phase 2.’’ 

In accordance with the Paperwork 

Reduction Act, 44 U.S.C. 3501–3520, 

AHRQ invites the public to comment on 

this proposed information collection. 

DATES: Comments on this notice must be 

received by October 29, 2010. 

ADDRESSES: Written comments should 

be submitted to: Doris Lefkowitz, 

Reports Clearance Officer, AHRQ, by email at doris.lefkowitz@AHRQ.hhs.gov. 

Copies of the proposed collection plans, 

data collection instruments, and specific 

details on the estimated burden can be 

obtained from the AHRQ Reports 

Clearance Officer. 

FOR FURTHER INFORMATION CONTACT: 

Doris Lefkowitz, AHRQ Reports 

Clearance Officer, (301) 427–1477, or by 

e-mail at 

doris.lefkowitz@AHRQ.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Proposed Project 

Understanding Patients’ Knowledge and 

Use of Acetaminophen—Phase 2 

AHRQ proposes a cross-sectional 

prospective survey to identify issues 

that relate to the misuse and overdosing 

of over-the-counter (OTC) 

acetaminophen. The survey was 

developed based on results from a 

previous data collection (OMB control 

number 0935–0154, approved on 10/13/ 

2009). Acetaminophen is the most 

widely used analgesic and antipyretic 

drug in the U.S. When appropriately 

used, it is a very safe agent. However, 

a single large overdose, or several 

supratherapeutic dosages in a short 

period of time, has been associated with 

acute liver failure, which can occur with 

dosages over 250 mg/kg over a 24-hour 

period, or > 12 g in an adult. Toxicity 

from acetaminophen has been on the 

rise in the past 3 decades, and is now 

the most common cause of acute liver 

failure in the U.S., surpassing viral 

hepatitis. 

This project has the following aims: 

(1) To estimate frequency of use, 

knowledge, and practices regarding use 

of OTC acetaminophen, and 

(2) To evaluate potential determinants 

of misuse in community-based samples. 

This information will be useful for 

policy makers to consider and to 

evaluate regulations and legislation with 

respect to the distribution, dispensing 

and sales of OTC acetaminophen. 

This study is being conducted by 

AHRQ through its contractor, the 

University of Texas. This project 

supports AHRQ’s Centers for Education 

and Research on Therapeutics initiative 

to promote the safe and effective use of 

therapeutics. See 42 U.S.C. 299b–1(b). It 

also supports AHRQ’s mandate for the 

inclusion of priority populations. See 42 

U.S.C. 299(c). 

Method of Collection 

To achieve the projects’ aims the 

following data collections will be 

implemented: 

(1) Surveys with parents of young 

children (age < 8 years). The purpose of 

this survey is to learn how parents 

administer acetaminophen to their 

children and to identify determinants of 

misuse of acetaminophen; 

(2) Surveys with adolescents (ages 13 

to 20). The purpose of this survey is to 

learn how adolescents use 

acetaminophen and to identify 

determinants of misuse of 

acetaminophen; 

(3) Surveys with adults (21 to 65 years 

of age). The purpose of this survey is to 

learn how adults use acetaminophen 

and to identify determinants of misuse 

of acetaminophen; 

(4) Surveys with adults (greater than 

65 years of age). The purpose of this 

survey is to learn how older adults use 

acetaminophen and to identify 

determinants of misuse of 

acetaminophen, particularly in regards 

to age-related factors. 

Data will be collected in person using 

paper questionnaires administered by 

the project personnel. 

Estimated Annual Respondent Burden 

Exhibit 1 shows the estimated 

annualized burden hours for the 

respondent’s time to participate in this 

project. Each of the four questionnaires 

used in the planned face-to-face surveys 

will require approximately 30 minutes 

to complete. The total annualized 

burden for all participants is estimated 

to be 400 hours. 

Exhibit 2 shows the estimated 

annualized cost burden for the 

respondent’s time to participate in the 

project. The total annualized cost 

burden is estimated to be $8,361. 

EXHIBIT 1—ESTIMATED ANNUALIZED BURDEN HOURS

Data collection mode Number of 

respondents 

Number of 

responses per 

respondent 

Hours 

per response 

Total 

burden 

hours 

Surveys with Parents of Children < 8 years of age ......................................... 300 1 30/60 150 

Surveys with Adolescents (13 to 20 years of age) ......................................... 200 1 30/60 100 

Surveys with Adults (20 to 65 years) .............................................................. 150 1 30/60 75 

Surveys with Adults (greater than 65 years) ................................................... 150 1 30/60 75 


jlentini on DSKJ8SOYB1PROD with NOTICES